Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thoughts on catalyst in 2020 and timeline and your estimate on PPS/market cap? TIA
jfk....totally agree with you on this...sleeping giant. Yesterday accumulation was obvious to me
Nice move upwards on PPS like to see this move above $6.50 today
I agree Tilt and Merck written all over it IMHO!
Good luck Xena you will be in my prayers and may god bless you..
That is excellent information! Thank you Xena!!
I am new to AVXL and after some due diligence in November of last year I purchased 5k shares in December and January and my cost basis is $2.77. I really like the science here and PPS trend and recent news.
Question: What is Anavex manufacturing capability for 2-73 to produce with PA and what is expected time to ramp up to commercialization?
TIA and much appreciated
My condolences Umibe5690 to you and your family on your loss. Thank you for your contributions to this board!
Happy 66th Birthday Captain! Merry Christams as well!
sukus, I am on Fidelity platform as well and same thing for me. what trading platform allows you to put in a sell order much higher than $2.00?
Dr. Cloughesy at UCLA is also speaking at this GBM Summit
Timothy Cloughesy
Director, Neuro-Oncology Program, Professor
Day Two
Wednesday, December 11, 2019
9:40 am | Coaxing T-cells into Action: Leveraging a Rational & Logical Way to Develop Immunotherapies
UCLA
Dr. Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. His research has focused on clinical trials in brain cancer using targeted molecular/immune therapies with novel clinical trial design and biomarkers in brain cancer. He is the global PI for the master protocol GBM Agile.
Great find Follower and I found this interesting in Mr. Ganjei interview in a couple of questions he was asked which is the DCVax-L trial he references.
Well said and agree!
Great post...This last sentence in your post I found interesting as DCVax-L has an Expanded Access Program that had 27 clinics participating and expected to enroll about 100 patients. NWBO has never given any update on this study and would be interesting to know why.
https://clinicaltrials.gov/ct2/show/study/NCT02146066?term=dcvax#locn
Detailed Description:
Patients who are being screened under protocol 020221 who are not eligible for enrollment due to a) evidence of disease progression or pseudo-progression post chemo-radiation or b) insufficient (<5 doses) vaccine manufactured, and for whom the DCVax-L treatment was manufactured and released are eligible for this study.
Treatment Schedule:
Open label vaccine injections will be give per the associated 020221 protocol. Injections will be given at days 0, 10, 20, and at months 2, 4, 8, 12, 18, 24 and 30. There are no therapeutic restrictions, but guidelines for drug administration are recommended as per the 020221 protocol.
Data collected includes vaccine administration information, and any vaccine related adverse event. Patient MRIs will be collected centrally for future review. Patients will be followed for disease progression and survival.
Wow bookem3266, thanks for sharing this cancer story on your co-worker who is going through an incredibly challenging time in his life. God bless him and his family. Cancer touches so many people as we all know. He is in my thoughts and prayers today.
Wow longfellow95 thanks for sharing. Very disturbing article!
SpotOn, what are your thoughts on Ucore and US government reliance and support to rare earth production and when do you see Ucore coming into production? TIA
KIPK, beautiful post and well said!
BETHESDA, Md. , May 30, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit hall at the 55th Annual ASCO Convention at the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical programs.
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
ASCO is the largest annual gathering of medical professionals in oncology, held every year at the beginning of June in Chicago. Over 30,000 medical professionals from all over the world attend to present and exchange information on the latest potential breakthroughs in cancer research and treatments.
Dr Bosch's presentation will provide updates about the Company's DCVax-Direct and DCVax-L programs. The DCVax-Direct updates will include follow-up data from the Company's Phase I trial for all types of inoperable solid tumors, and plans for further trials.
The DCVax-L updates will include a progress report on the Company's work on preparations necessary for unblinding of the Company's Phase III trial of DCVax-L for Glioblastoma brain cancer.
Dr. Bosch's presentation will be webcast live at: https://nwbio.com/update-on-dc-vax-at-asco-2019/ The presentation will also be available on the home page of the Company's website (www.nwbio.com) after the ASCO conference ends.
The industry theater presentation will not be an official presentation of the 2019 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO® or Conquer Cancer®, the ASCO Foundation, and not CME-accredited.
About Northwest Biotherapeutics(NWBO)
Northwest Biotherapeutics (NWBO) is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial, and is preparing for further trials. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing and expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nw-bio-to-present-updates-on-dcvax-clinical-programs-in-industry-theater-presentation-at-asco-300859234.html
SOURCE Northwest Biotherapeutics(NWBO)
Welcome back tctrader!! I always liked reading your posts!
You can email him from the link that was posted.
Another day closes with a 911 final trade....
Thanks for the charting Sojourner, we longs appreciate your post with TA updates.
Totally agree Flip! People are dying every day from glioblastoma! God bless patients.
Thanks Sojo for your charts with comments as I always enjoy getting your technical analysis. GLTA to all patients and longs!
Merrimack 0 for 3 as it dumps cancer drug over safety fears, axes staffers (again)
by Ben Adams | Apr 5, 2019 4:29am
My Comment: You have to love DCVax Safety Profile!
Strong buy volume today and being accumulated nicely
From Yahoo message board:
Oppenheimer comments...
Celsion Corporation (CLSN) reported 4Q18 and provided a business update to investors last Friday. In focus, CLSN is approaching two interim analyses for ThermoDox from the fully-enrolled Phase 3 OPTIMA study expected in 3Q19 and 2020. We are encouraged by the DMC's December 18, 2018 assessment, highlighting a median PFS of 21.2 months as of the October 4th data cut-off. In addition, the earlier-stage OVATION II with GEN-1 continues to progress, enrolling patients for dose selection and safety. With 2018 year-end cash of $27.7 million, CLSN has ample runway to reach these meaningful potential value-creating catalysts, in our view. We remain bullish.
Please post link....
It sure looks that way as last trade of day at 911 shares!
http://www.pennystockdream.com/Market-Maker-Signals
Could be 331-223= 108 alive as noted in the journal signed of by the 65 doctors listed?
I agree and reason why I was surprised he used that 223 number at 2 years not sure what to make of it just found it interesting coming from a German neurosurgeon ?
Literature Review
Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons
Author links open overlay panelJacob S.Young1FaraDayani2Ramin A.Morshed1HidehoOkada1Manish K.Aghi1
My comment: When you google DCVax UK and search within a week this article medical journal appeared
https://doi.org/10.1016/j.wneu.2018.12.222
Great find Lykiri! He mentioned 223 patients at 2 years which I found interesting number if he meant alive?
Well said Senti!
Soho, thank you for your continued TA, there are many who appreciate it due to your calls being very good. Thank you and good luck to patients, caregivers in this DCVax-L trial for glioblastoma.
Nice volume today in first 2.5 hours and PPS trending up nicely!
You have to like all the Director's/Management buying stock!
Fraunhofer GMP Cell and Gene Therapy Unit nows shows DCVax-L as finished project. Top line results coming soon IMO. GLTA patients and their families, NWBO longs